NeuroGyn Genital Neuromodulation System for iOAB Treatment

NCT ID: NCT06529198

Last Updated: 2024-07-31

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2026-04-01

Brief Summary

The NeuroGyn study is designed to evaluate the safety and effectiveness to the NeuroGyn Genital Neuromodulation System as an aid in the treatment of the symptoms of idiopathic overactive bladder in patients who have failed or could not tolerate more conservative treatments.

Detailed Description

not provided

Conditions

Overactive Bladder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

treatment

Patient are undergoing neuromodulatioon

Group Type: EXPERIMENTAL

NeuroGyn Genital Neuromodulation System

Intervention Type: DEVICE

Genital Neuromodulation

Interventions

NeuroGyn Genital Neuromodulation System

Genital Neuromodulation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 18 years of age and older (adult and older adult, all sexes)
• Diagnosed (urodynamic testing) with idiopathic overactive bladder (iOAB)
• Symptoms of urinary urgency, frequency, and/or urge incontinence for at least 6 months
• Failed conservative treatments (e.g., lifestyle modifications, medications)
• Willing and capable of providing informed consent
• Capable of participating in all testing associated with this clinical investigation
• Patients have already undergo a successful GNS-test phase with adhesive electrodes (reduction symptoms greater equal or more than 50%)

Exclusion Criteria

• History of pelvic surgery affecting the pubic bone or genital nerves
• Current urinary tract infection
• Neurological conditions affecting bladder function (neurogenic OAB)
• Pregnancy or planning to become pregnant during the study period
• Contraindications to local anesthesia or surgery
• Female patients with significant prolapse (i.e., prolapse beyond the introitus).
• Patients with primary stress incontinence and primary pelvic pain symptoms.
• Patients with less than 12 months from last intravesical botulinum toxin A therapy
• Patients with mechanical infravesical obstruction and/or Interstitial Cystitis.
• Vulnerable patients with co-morbid conditions should be excluded from this study. These co-morbid conditions include all pathologies of the cardiovascular system (Angina Pectoris, Infarct, Thrombose, Embolie, Hypertonia), pulmonary system (asthma, COPD, chr. Bronchitis), intestinal system (morbus Crohn, diverticulitis..) and any malignant disease. These co-morbid conditions also include neurologic diseases (i.e., stroke, multiple sclerosis, spinal cord injury), sacral dermal pathological conditions, congenital or other anatomical sacral anomalies (e.g. spina bifida, sacral agenesis, trauma sequelae), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTIs), gross hematuria, prior pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate), deeply infiltrating endometriosis of the pelvic plexus, sacral plexus or of the bladder, Reiter´s syndrome, and pelvic radiation.
• Patients suffering from other CNS disorders (mental disorders, severe psychological problems, cerebrovascular accident less than 6 months ago).
• Patients suffering from polydipsia/polyuria are excluded from the study. Similarly, patients suffering from diabetes insipidus (DI) and diabetes mellitus (DM) are also excluded from the study.
• A female with a positive urine pregnancy test
• A female who is breastfeeding
• Allergies again local anesthesia (Lidocain), Tranquillizers and Antibiotics

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prof. Dr. med. Marc Possover

OTHER

Sponsor Role: lead

Responsible Party

Prof. Dr. med. Marc Possover

PhD MD

Responsibility Role: SPONSOR_INVESTIGATOR

Central Contacts

Marc Possover, PhD

Role: CONTACT

m.possover@possover.com

+41797507595

Other Identifiers

NeuroGyn AG

Identifier Type: -

Identifier Source: org_study_id